IVIg attenuates CIDP-mediated autoimmunity via anti-idiotypic antibodies (Svačina et al. 2019), reduction of pro-inflammatory cytokines and chemokines (i.e., interleukin-6 [IL-6], or macrophage inflammatory protein-1α [MIP-1α], Hartung 2008; Ritter et al. 2014; Kajii et al. 2014), and by enhancing the expression of CD32b receptors on B cells and monocytes (Tackenberg et al. 2009). Here, IL6 is linked to Autoimmunity.